DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma

Bibliographic Details
Main Authors:	Gupta, A, Love, S, Schuh, A, Collins, L, Thomason, A, Asher, R, Lisle, R, Churchman, M, Shanyinde, M, Plummer, R, Nathan, P, Danson, S, Ottensmeier, C, Lorigan, P, Larkin, J, Middleton, MR
Format:	Journal article
Published:	2013

Similar Items